13 Best Biotech Penny Stocks To Buy Now

Published on November 29, 2022 at 5:43 pm by Fatima Farooq in Hedge Funds, News

In this article, we will be taking a look at the 13 best biotech penny stocks to buy now. To skip our detailed analysis of these stocks, you can go directly to see the 5 Best Biotech Penny Stocks To Buy Now.

Biotechnology is a sector that has long been contributing to the improvement of our quality of life. Companies operating in this sector have been working to address global health concerns related to infectious and age-related diseases. As a result, many investors today see immense potential for profit and gain in the biotech sector since biotech companies offer new sources of return and diversification of risk when investing in this sector.

Major companies within the biotech sector today include AbbVie Inc. (NYSE:ABBV), Pfizer Inc. (NYSE:PFE), and Bristol-Myers Squibb Company (NYSE:BMY), among more. At the same time, smaller-scale companies like the ones covered in our list below also offer attractive investment opportunities provided they have the financial backing to go through with their ongoing operations. As a result of the growing popularity of the biotech sector on the market, the number of public companies in this sector has increased significantly over the past few years. According to an S&P Dow Jones Indices report from October 2019, in 2015, there were 442 public biotech companies compared to 316 companies in 2012.

The biotech sector also shows a high return potential, based on the historical performance of the S&P Biotechnology Select Industry Index. In 2019, this index outperformed the S&P Pharmaceutical Select Industry Index and the S&P 500 consistently, posting absolute total returns of 22% in that year. Over the three years preceding 2019, this index had annualized returns of 17.7%, versus the same of -0.9% for the S&P Pharmaceutical Select Industry Index and 14.2% for the S&P 500.

louis-reed-pwcKF7L4-no-unsplash

Our Methodology

We have selected penny stocks in the biotech sector trading below $5. These stocks have high liquidity allowing them to continue funding their ongoing operations over the coming years, based on their cash and cash equivalent figures for the third quarter. We have ranked them based on the number of hedge funds holding stakes in them, from the lowest to the highest.

Best Biotech Penny Stocks To Buy Now

13. Histogen Inc. (NASDAQ:HSTO)

Number of Hedge Fund Holders: N/A

Share Price as of November 29: $1.06

Histogen Inc. (NASDAQ:HSTO) is a biotech company focusing on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products. The company is based in San Diego, California.

In the third quarter of 2022, Histogen Inc. (NASDAQ:HSTO) had an EPS of -$1.01, beating estimates by $0.48. This July, the company also entered into a securities purchase agreement with a single healthcare-focused institutional investor. The agreement was for the issuance of 1.77 million shares of common stock, Series A warrants to buy an additional 1.77 million, and Series B warrants to buy an aggregate of 1.77 million at a price of about $2.818 per share. Histogen Inc. (NASDAQ:HSTO) is expected to draw in gross proceeds of approximately $5 million from the agreement.

However, Histogen Inc. (NASDAQ:HSTO), unlike AbbVie Inc. (NYSE:ABBV), Pfizer Inc. (NYSE:PFE), and Bristol-Myers Squibb Company (NYSE:BMY), is a high-risk stock.

12. electroCore, Inc. (NASDAQ:ECOR)

Number of Hedge Fund Holders: 3

Share Price as of November 29: $0.35

electroCore, Inc. (NASDAQ:ECOR) is a commercial-stage medical device company working to develop and commercialize a range of non-invasive vagus nerve stimulation therapies. The company’s gammaCore product is a prescription-only therapy for the acute treatment of migraines and episodic cluster headaches in adults. The company is based in Rockaway, New Jersey.

electroCore, Inc.’s (NASDAQ:ECOR) revenue in the third quarter of 2022 was $2 million, representing a growth of 33.3% year-over-year. The company’s cash, cash equivalents, and restricted cash as of September 30 stood at $21.9 million. In the fourth quarter, electroCore, Inc. (NASDAQ:ECOR) expects net revenues between $2.2 million and $2.3 million, versus the consensus estimate of $1.91 million. The company also guided for net cash usage between $4 million and $4.5 million.

Renaissance Technologies was the largest stakeholder in electroCore, Inc. (NASDAQ:ECOR) in the third quarter, holding 259,660 shares worth $105,000. In total, three hedge funds were long the stock, with a total stake value of $138,000.

11. Vaccinex, Inc. (NASDAQ:VCNX)

Number of Hedge Fund Holders: 3

Share Price as of November 29: $0.49

Vaccinex, Inc. (NASDAQ:VCNX) is a healthcare and biotech company focusing on the treatment of cancer and neurodegenerative disease. The company is based in Rochester, New York.

This November, Vaccinex, Inc. (NASDAQ:VCNX) closed a private placement of 7.14 million shares priced at $0.529 each. The company was able to generate about $3.8 million through this direct stock offering, including $2.9 million worth of shares being bought by the company’s management. Vaccinex, Inc. (NASDAQ:VCNX) now intends to use the net proceeds from the offering to fund its ongoing development and clinical trials for its lead drug, pepinemab, used in the treatment of cancer and neurodegenerative disease. The company also reported in its third-quarter earnings report that its cash and cash equivalents and marketing securities for the quarter were $7.2 million.

Three hedge funds were long Vaccinex, Inc. (NASDAQ:VCNX) in the third quarter, and four hedge funds were long the stock in the previous quarter. Their total stake values were $1.1 million and $2.5 million, respectively.

10. Regulus Therapeutics Inc. (NASDAQ:RGLS)

Number of Hedge Fund Holders: 3

Share Price as of November 29: $1.70

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a clinical-stage biopharmaceutical company working to discover and develop drugs targeting micro-RNAs to treat a variety of diseases in the US. The company is based in San Diego, California.

On November 7, Canaccord’s Whitney Ijem initiated coverage of Regulus Therapeutics Inc. (NASDAQ:RGLS) with a Buy rating and a $9 price target.

This September, Regulus Therapeutics Inc. (NASDAQ:RGLS) announced topline data from its Phase 1 Single-Ascending Dose Trial for kidney disease candidate RGLS8429. RGLS8429 is a drug designed to target Autosomal Dominant Polycystic Kidney Disease. The company’s data showed that the drug was well-tolerated with no serious side effects. Regulus Therapeutics Inc. (NASDAQ:RGLS) shares rose by about 15% in light of this trial’s success. The company also reported in November that its cash, cash equivalents, and marketable securities for the third quarter stood at $45.3 million.

Out of the three hedge funds long Regulus Therapeutics Inc. (NASDAQ:RGLS) in the third quarter, DAFNA Capital Management was the largest stakeholder in the company. The fund held 555,555 shares in the company, worth $944,000 out of the total stake value of $1.3 million.

9. Vascular Biogenics Ltd. (NASDAQ:VBLT)

Number of Hedge Fund Holders: 3

Share Price as of November 29: $0.15

Vascular Biogenics Ltd. (NASDAQ:VBLT) is another clinical-stage biopharmaceutical company on our list. It develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the US.

This November, Vascular Biogenics Ltd. (NASDAQ:VBLT) reported that for the third quarter, its EPS of -$0.12 was in line with estimates, while its $0.5 million revenue was up 150% year-over-year and beat estimates by $0.3 million. The company’s cash, cash equivalents, short-term bank deposits, and restricted bank deposits stood at $27.7 million. This figure is expected to fund the company’s current operating expenses and capital expenditures for at least 12 months.

Our hedge fund data shows three funds long Vascular Biogenics Ltd. (NASDAQ:VBLT) in the third quarter and four funds long the stock in the previous quarter. Their total stake values were $84,000 and $7.2 million, respectively.

8. vTv Therapeutics Inc. (NASDAQ:VTVT)

Number of Hedge Fund Holders: 3

Share Price as of November 29: $0.84

vTv Therapeutics Inc. (NASDAQ:VTVT) develops orally administered treatments for diabetes. The biotech company is based in High Point, North Carolina.

In the third quarter, vTv Therapeutics Inc. (NASDAQ:VTVT) reported that its cash position as of this September was $15.3 million, compared to $13.4 million in December 2021. This July, the company also announced that it is raising $10 million via an equity investment by CinPax, a unit of CinRx Pharma. The stock surged by 18.7% in light of the news.

Samsara BioCapital was the largest stakeholder in vTv Therapeutics Inc. (NASDAQ:VTVT) in the third quarter, holding 1.6 million shares worth $1.6 million. In total, three funds were long the stock, with a total stake value of $1.7 million.

7. MediciNova, Inc. (NASDAQ:MNOV)

Number of Hedge Fund Holders: 4

Share Price as of November 29: $2.66

MediciNova, Inc. (NASDAQ:MNOV) develops novel and small molecule therapeutics to treatment serious diseases with unmet medical needs in the US. It is based in La Jolla, California.

MediciNova, Inc. (NASDAQ:MNOV) had an EPS of -$0.07 in the third quarter, beating estimates by $0.02. Over the past three months, the company’s stock has outperformed the S&P 500, rising by 3.15% while the S&P 500 declined by 2.31%.

MediciNova, Inc. (NASDAQ:MNOV) was found among the 13F holdings of four hedge funds in the third quarter, with a total stake value of $1.2 million. In comparison, five funds were long the stock in the previous quarter, with a total stake value of $1.5 million.

MediciNova, Inc. (NASDAQ:MNOV), like AbbVie Inc. (NYSE:ABBV), Pfizer Inc. (NYSE:PFE), and Bristol-Myers Squibb Company (NYSE:BMY), is an attractive biotech stock hedge funds are beginning to consider.

6. Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE)

Number of Hedge Fund Holders: 4

Share Price as of November 29: $0.42

Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) is a biopharmaceutical company that develops immunomodulatory therapies to treat pain from osteoarthritis in the US. The company is based in Englewood, Colorado.

In the second quarter, Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) reported an EPS of -$0.15, beating estimates by $0.15. This March, the company’s cash and cash equivalents stood at $28.8 million.

Our hedge fund data shows 4 funds long Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) in the third quarter. Their total stake value was $204,000.

Click to continue reading and see the 5 Best Biotech Stocks To Buy Now.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

13 Best Biotech Penny Stocks To Buy Now

Published on November 29, 2022 at 5:43 pm by Fatima Farooq in Hedge Funds, News

Best Biotech Penny Stocks To Buy Now

13. Histogen Inc. (NASDAQ:HSTO)

12. electroCore, Inc. (NASDAQ:ECOR)

11. Vaccinex, Inc. (NASDAQ:VCNX)

10. Regulus Therapeutics Inc. (NASDAQ:RGLS)

9. Vascular Biogenics Ltd. (NASDAQ:VBLT)

8. vTv Therapeutics Inc. (NASDAQ:VTVT)

7. MediciNova, Inc. (NASDAQ:MNOV)

6. Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE)

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff